Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.006.82%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.58M | -5.43M | -6.63M | -6.34M | -5.37M |
| Total Depreciation and Amortization | 2.00K | 2.00K | 2.00K | 3.70K | 5.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.21M | 1.21M | 2.18M | 1.88M | 1.59M |
| Change in Net Operating Assets | 1.78M | 891.60K | 1.08M | 1.36M | 437.50K |
| Cash from Operations | -2.59M | -3.33M | -3.37M | -3.09M | -3.33M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 2.39M | 2.51M | 2.08M | 2.21M | 2.34M |
| Total Debt Repaid | -271.20K | -273.00K | -247.80K | -289.30K | -300.10K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 225.00K | 850.00K | 1.00M | 1.00M | 1.00M |
| Cash from Financing | 2.34M | 3.09M | 2.83M | 2.92M | 3.04M |
| Foreign Exchange rate Adjustments | 800.00 | 600.00 | -400.00 | 100.00 | -100.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -245.60K | -238.50K | -541.80K | -172.90K | -293.40K |